OTC:BIXT
Bioxytran, Inc. (OTC:BIXT) is a clinical-stage pharmaceutical company focused on developing platform technologies using carbohydrate drug design to neutralize viruses and extend lifespans. The company’s approach involves analyzing Nuclear Magnetic Resonance (NMR) imaging data with artificial intelligence software to create novel carbohydrate structures. These structures target druggable proteins like the galectin fold. The company’s leading drug candidates have demonstrated promise in neutralizing viruses, with recent peer-reviewed research spotlighting the discovery of the galectin fold on viral spike proteins such as those found in COVID-19, RSV, and H1N1. Bioxytran’s technology shows potential for addressing various medical needs in virology, degenerative diseases, and hypoxia. The company’s primary candidate, Prolectin-M, aims to counter galectins involved in inflammatory, fibrotic, and malignant conditions. Additionally, BIXT is developing treatments for pulmonary fibrosis and stroke.
ProLectin-M and Covid-19
Bioxytran specializes in formulating oral Galectin inhibitors. Galectins play roles in antiviral defense, immune responses, and inflammation regulation, potentially influencing the course of COVID-19. ProLectin-M is the company’s oral galectin antagonist that aims to block viral entry and facilitate virus elimination. Designed initially for standard-risk COVID-19 patients, its broad-spectrum potential suggests applications for RSV and influenza. Recent clinical trials demonstrated that the drug achieved a 100% response rate of negative PCR tests by day seven, with an 88% response rate within 3 days. Additionally, no viral rebounds were observed in the treated population during the 14-day observation period. The company is preparing for a phase 3 clinical trial to seek regulatory approval. The trial, involving 40 patients, will be randomized and double-blind. Kevin Mayo, a University of Minnesota Professor and Bioxytran advisor, highlighted the discovery of a new viral binding region on spike proteins, facilitating the design of carbohydrate structures to neutralize viruses. This discovery, utilizing NMR imaging, represents a shift in virology towards carbohydrate-based neutralization, potentially revolutionizing antiviral therapies.
Hypoxia and Degenerative Diseases
Bioxytran is also developing treatments for hypoxic conditions, necrosis, and degenerative diseases that carry oxygen to affected areas for stroke, wound, and brain damage. Leveraging issued patents and proprietary technology, the company aims to develop drugs like BXT-25 for stroke treatment. BXT-25 is an injectable anti-necrosis drug designed for immediate use after an ischemic stroke. Administered intravenously, it transports oxygen to the brain by crossing the blood-brain barrier. The molecule is engineered to be about 5,000 times smaller than a red blood cell. Bioxytran’s patent portfolio includes a method patent related to co-polymer technology and exclusive rights to FDA-approved OxySense technology for real-time monitoring of oxygen supply to the brain. This technology, licensed from MDX LifeSciences, enables rapid and cost-effective development of safe molecules addressing medical needs resulting from hypoxia.
Shingles
On March 6, 2024, Bioxytran announced a preprint showing promising results in clearing shingles lesions and reducing neuralgia within 48-72 hours using a topical galectin-3 antagonist. While vaccines exist for shingles prevention, effective antiviral therapies for treating outbreaks and pain are limited. Further research is needed to explore expanded clinical trials with galectin antagonists, with the goal of transforming shingles and neuralgia management.
Funding
To ensure continuity and product development, Bioxytran’s management team remains focused on securing additional funding through public or private securities sales, debt financing, short-term bank loans, or a combination thereof. Management is targeting raising $5,300,000 to cover existing debts and support business growth for approximately 15 months.
Conclusion
Bioxytran is positioned as an active player in pharmaceutical innovation, particularly in carbohydrate drug design, with aspirations to tackle a broad spectrum of medical challenges including viral infections, degenerative diseases, and hypoxia. The company’s leading candidate ProLectin-M shows promising potential in addressing COVID-19 and other bacterial infections. Furthermore, ongoing developments in treatments for hypoxia and shingles suggest broader avenues for potential impacts in healthcare. Ongoing testing and clinical trials are necessary to thoroughly assess the efficacy and safety of these treatments. The company’s ability to secure additional funding remains a critical factor in sustaining progress and advancing research and development initiatives.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
Full Disclaimer HERE.
